No CrossRef data available.
Article contents
Therapy group following a Ketamine treatment – a case report of a patient with resistant depression
Published online by Cambridge University Press: 01 September 2022
Abstract
There are some patients that remain resistant to treatment for major depressive disorder - who were treated with two or more different medications, and did not demonstrate any improvement in their mental-state. These patients can be treated with a new treatment – Esketamine. The recommended Esketamine treatment protocol includes 8-treatment sessions, each session lasts about two hours. In our clinic, we added a therapy group after each treatment. The therapy group is led by two co-therapist and lasts 30 minutes. The patients are invited to share their experiences from the session.
We will present a case report of a 44 year old man, that suffers from a major-depression for years, with symptoms such as loss of energy, recurrent thoughts of death and a decrease in functioning. He was treated with different medications, but there was no improvement in his mental state.
For the last six months, he was treated with Esketamine and also participated in the therapy group.
According to content that he raised in the sessions of the therapy group and following conversations with him and with his close environment, we observed a clinical improvement in his condition – a positive mood, a decrease of the thoughts of death, an increase in his function at work and at home.
He reported that the improvement is more significant because of the therapy group – he found a peer group, a place to process his treatment experience and to share his feelings and thoughts. We will present vignettes to demonstrate.
No significant relationships.
- Type
- Abstract
- Information
- European Psychiatry , Volume 65 , Special Issue S1: Abstracts of the 30th European Congress of Psychiatry , June 2022 , pp. S563
- Creative Commons
- This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
- Copyright
- © The Author(s), 2022. Published by Cambridge University Press on behalf of the European Psychiatric Association
Comments
No Comments have been published for this article.